BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.
Valuation and Earnings
This table compares BioNexus Gene Lab and IceCure Medical”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioNexus Gene Lab | $7.43 million | 0.72 | -$1.60 million | ($1.28) | -1.73 |
| IceCure Medical | $3.38 million | 8.62 | -$15.06 million | ($0.24) | -1.50 |
Analyst Recommendations
This is a summary of current recommendations for BioNexus Gene Lab and IceCure Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioNexus Gene Lab | 1 | 0 | 0 | 0 | 1.00 |
| IceCure Medical | 1 | 1 | 1 | 0 | 2.00 |
IceCure Medical has a consensus price target of $2.64, indicating a potential upside of 633.98%. Given IceCure Medical’s stronger consensus rating and higher possible upside, analysts plainly believe IceCure Medical is more favorable than BioNexus Gene Lab.
Profitability
This table compares BioNexus Gene Lab and IceCure Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioNexus Gene Lab | -24.26% | -30.18% | -24.85% |
| IceCure Medical | -445.61% | -221.04% | -118.89% |
Insider and Institutional Ownership
18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
BioNexus Gene Lab has a beta of 4.98, indicating that its share price is 398% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.
